The Vest APX System utilizes high frequency chest wall oscillation to mobilize secretions and reduce pulmonary exacerbations for patients with chronic respiratory conditions.
RT’s Three Key Takeaways:
- Secretions Mobilization: The device uses oscillating positive pressure pulses to inflate and deflate a garment, helping to dislodge and move mucus into larger airways for clearance.
- Clinical Outcomes: Research indicates that high frequency chest wall oscillation therapy can result in fewer hospitalizations, physician office visits, and acute exacerbations for patients with bronchiectasis.
- Enhanced Design: The next-generation system features a 7-inch LED touch-screen, magnetic quick-attach hoses, and a variety of garment sizes to improve patient comfort and therapy adherence.
Baxter has introduced the Vest APX System, a next-generation high frequency chest wall oscillation (HFCWO) device designed to mobilize bronchial secretions and improve airway clearance for patients with chronic respiratory conditions.
The system uses oscillating positive pressure pulses to rapidly inflate and deflate a garment, which applies gentle pressure to the chest wall. This process helps dislodge mucus from small airways and move it toward larger airways where it can be cleared through coughing or suctioning.
The Vest APX System is cleared by the Food and Drug Administration (FDA) to provide airway clearance therapy when external manipulation of the thorax is the physician’s choice of treatment. According to Baxter, the therapy can help patients maintain better lung health and reduce pulmonary hospitalizations and exacerbations. Recent research has shown that HFCWO use results in fewer physician office visits and acute exacerbations for those living with bronchiectasis.
The device features a compact, lightweight control unit equipped with a 7-inch LED touch-screen and preprogrammed protocols. Design updates include magnetic quick-attach hoses and garments available in various sizes and patterns with quick-fastening Velcro brand closures. The unit also includes a locking screen to prevent inadvertent setting changes and a luggage-style carrying case for travel.
The system is intended for patients with respiratory insufficiency, including those with bronchiectasis, cystic fibrosis, and certain neuromuscular diseases. It can be used alongside aerosol or nebulizer treatments, as there is no contraindication for conducting both treatments simultaneously.
Baxter also offers the CARE Connex Program, which provides services throughout the patient journey, including assistance with insurance coverage. The Vest APX System is generally covered by Medicare, Medicaid, and private commercial insurance when prescribed by a doctor.
Source
- https://respiratory-therapy.com/products-treatment/monitoring-treatment/therapy-devices/products-2025-secretion-clearance-suction/
- https://www.hillrom.com/en/products/the-vest-apx-system
